18 -RRB- responsible for the majority of cervical cancers in North America , '' said Sarah Alspach , a GlaxoSmithKline spokeswoman . `` But approximately 25 percent of cervical cancers are caused by other cancer-causing HPV types . Cervarix has been shown to reduce the incidence of pre-cancers resulting from cancer-causing virus types beyond 16 and 18 . '' The vaccine will be available this year , according to GSK , which did not divulge the price . Cervarix will be competing with Merck & Company 's Gardasil , the first cervical cancer vaccine , which won FDA approval in June 2006 . Gardasil , for girls and women ages 9 to 26 , prevents against cervical , vulvar and vaginal cancers and protects against HPV types 11 , 16 and 18 . Gardasil 's approval has been broadened by the FDA to include an indication for boys and young men ages 9 through 26 for prevention of genital warts caused by HPV types 6 and 11 . `` This vaccine is the first preventive therapy against genital warts in boys and men ages 9 through 26 , and , as a result , fewer men will need to undergo
WASHINGTON -LRB- CNN -RRB- -- The Food and Drug Administration approved a second vaccine intended to protect against cervical cancer . GlaxoSmithKline has manufactured a vaccine for the prevention of cervical cancer . Cervarix , manufactured by GlaxoSmithKline , was approved Friday for prevention of cervical cancer and pre-cancerous lesions caused by human papillomavirus -LRB- HPV -RRB- types 16 and 18 . The vaccine is approved for use in girls and women ages 10 to 25 years and is to be administered in three doses . After the initial shot , the second and third doses are to be given within six months . `` The licensure of Cervarix adds another option in the prevention of cervical cancer , '' said Dr. Karen Midthun , acting director of the FDA 's Center for Biologics Evaluation and Research . `` It has the potential to save lives from cervical cancer as well as reduce the need for biopsies and invasive procedures associated with the necessary follow-up from abnormal Pap tests . '' According to GlaxoSmithKline , the vaccine is 70 percent effective against pre-cancerous lesions , regardless of HPV type . `` The vaccine contains two HPV types -LRB- 16 &